Novartis AG ADR (NYSE:NVS) shares, rose in value, with the stock price down by -1.14% to the previous day’s close as strong demand from buyers drove the stock to $95.79.
Actively observing the price movement in the last trading, the stock closed the session at $96.89. The value of beta (5-year monthly) was 0.46 whereas the PE ratio was 13.41 over 12-month period. Referring to stock’s 52-week performance, its high was $108.78, and the low was $88.86. On the whole, NVS has fluctuated by -6.67% over the past month.
The company’s Forward Dividend Ratio is 3.78, with its dividend yield at 3.94%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $1.69, which is expected to increase to $1.89 for fiscal year $7.12 and then to about $7.85 by fiscal year 2025. Data indicates that the EPS growth is expected to be 3.20% in 2025, while the next year’s EPS growth is forecast to be 10.30%.
Analysts have estimated the company’s revenue for the quarter at $11.48 billion, with a low estimate of $11.44 billion and a high estimate of $11.52 billion. According to the average forecast, sales growth in current quarter could jump down -9.20%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $48.03 billion, representing an increase of 5.70% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that NVS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 2.01, with the price of NVS currently trading nearly -1.35% and -4.85% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.42, while the 7-day volatility ratio is showing 1.15% which for the 30-day chart, stands at 0.94%. Furthermore, Novartis AG ADR (NVS)’s beta value is 0.54, and its average true range (ATR) is 1.37.
A comparison of Novartis AG ADR (NVS) with its peers suggests the former has fared considerably weaker in the market. NVS showed an intraday change of -1.14% in last session, and over the past year, it grew by 8.29%%.
Data on historical trading for Novartis AG ADR (NYSE:NVS) indicates that the trading volumes over the past 10 days have averaged 1.66 million and over the past 3 months, they’ve averaged 1.45 million. According to company’s latest data on outstanding shares, there are 2.04 billion shares outstanding.
Nearly 0.00% of Novartis AG ADR’s shares belong to company insiders and institutional investors own 7.28% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.53 million shares as on Mar 15, 2024, resulting in a short ratio of 2.77. According to the data, the short interest in Novartis AG ADR (NVS) stood at 0.20% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 4.12 million. The stock has fallen by -5.13% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NVS stock heading into the next quarter.
